Singleiv Administration News Today

Designing a novel ISL to improve the poor water solubility and low bioavailability of isoliquiritigenin for the treatment of acute ischemic stroke. Read more

This Year - BEDFORD, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today the first scientific presentation of data from IND-enabling studies with its HMI-203 gene therapy development candidate for Hunter syndrome (MPS II). The results from Homologys in vivo approach demonstrated the potential of HMI-203 to address peripheral manifestations in the murine disease model and showed that HMI-203 crossed the b...